COVID-19 Vaccination in North Sulawesi Grows Only 4% in a Week

North Sulawesi Province ranks among the lowest 10 provinces in terms of first-dose COVID-19 vaccination coverage for the general public. This ranking is based on weekly growth.

As of August 19, 2021, 217,430 people in North Sulawesi had received their first dose of the vaccine. Compared to the previous week, this represents a 4% increase. The week before, only 207,680 people had been vaccinated.

Out of 34 provinces, North Sulawesi ranks 33rd in terms of weekly vaccination growth. The top five provinces with the highest weekly growth were East Kalimantan (73.7%), West Papua (54.5%), Central Sulawesi (54.2%), North Kalimantan (47.9%), and Lampung (32.6%).

Over the past seven days, an average of 1,392 people in North Sulawesi received their first dose per day. Currently, a total of 779,430 people in the province have received their first dose, and 298,320 have received their second dose.

As shown in the chart, the trend of vaccination for the general public in North Sulawesi over the past week shows an upward but slow trend. This chart indicates that efforts to accelerate vaccination still need a boost, especially for the second dose, which has only reached 14.34% of the target.

Further details on vaccination in the province include: For healthcare workers, with a target of 21,780 individuals, 109.83% of the target (21,780 individuals) has received the first dose, and 95.47% (20,800 individuals) have received the second dose.

For public service workers, with a target of 194,980 individuals, 211.86% of the target (413,080 individuals) have received the first dose, and 92.86% (181,050 individuals) have received the second dose.

For the elderly population, with a target of 259,460 individuals, as of Thursday, August 19th, 29.64% of the target (76,890 individuals) have received the first dose, and 10.26% (26,620 individuals) have received the second dose.

For the third phase, targeting adolescents aged 12-17, with a target of 245,340 individuals, 19.61% of the target (48,100 individuals) have received the first dose, and 9% (22,700 individuals) have received the second dose.